LIMITATIONS AND FUTURE DIRECTION
schizophrenia
This was a double‐blind, placebo‐controlled, prospective study with adequate sample size. However, the low dose of 400 or 800 mg has been the major limitation. A multisite study using a differential dosing of L‐Carnosine (1.5–2 g), longer follow up, utility of newer scales such as BNSS (Brief Negative Symptoms Scale) or CAINS (Clinical Assessment Interview for Negative Symptoms) and Anticholinergic burden assessment may throw more conclusions on the efficacy of the drug. Additionally, prospectively measuring serum concentrations of alanine and glutamate in an L‐Carnosine study can also establish these as putative inflammatory biomarkers in schizophrenia.